Clinical Research Directory
Browse clinical research sites, groups, and studies.
Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium
Sponsor: Hugh Taylor
Summary
This study will assess the use of autologous bone marrow stem cells mobilization using 1,1'-\[1,4-phenylenebis-(methylene)\]-bis-1,4,8,11-tetraazacyclotetradecane (PLERIXAFOR) as an effective medical therapy for the treatment of Asherman's Syndrome (AS), Atrophic Endometrium (AE) and Recurrent Implantation Failure (RIF).
Official title: Bone Marrow Derived Stem Cells Mobilization for Treatment of Asherman's Syndrome, Atrophic Endometrium, and Recurrent Implantation Failure
Key Details
Gender
FEMALE
Age Range
18 Years - 40 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2023-11-01
Completion Date
2027-12
Last Updated
2025-11-12
Healthy Volunteers
Yes
Interventions
Plerixafor
A 20mg single dose of PLERIXAFOR is administered subcutaneously the evening prior to scheduled standard of care surgery for women with AS, AE or RIF for peripheral mobilization of stem cells. For subjects weighing \>83 kilogram, the dosing is a single dose of 0.24 milligram per kilogram.
Locations (1)
Yale Fertility Center
Orange, Connecticut, United States